

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
TECHNOLOGY APPRAISAL PROGRAMME**

Equality impact assessment – Scoping

STA: Enzalutamide for the treatment of metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen

Batch 27

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes: the potential for a subpopulation comprised of transgendered people was raised during the scoping workshop. However, NICE representatives clarified that this population is already included in the overall population of 'adults with metastatic hormone refractory prostate cancer which has been previously treated with a docetaxel-containing chemotherapy regimen'

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Not required, as transgendered people are already included within the population of 'adults'.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No change required.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

None have been identified.

Approved by Associate Director (name): Elisabeth George

Date: 24/04/13